Analyst Price Target is $1.84
▲ +176.40% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Isoray in the last 3 months. The average price target is $1.84, with a high forecast of $3.00 and a low forecast of $1.00. The average price target represents a 176.40% upside from the last price of $0.66.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Isoray. This rating has held steady since November 2019, when it changed from a Hold consensus rating.
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.